Endogenous GLP-1
GLP-1 is an incretin hormone from intestinal L-cells that enhances glucose-dependent insulin secretion and influences appetite pathways. Native peptide is short-lived due to DPP-4 cleavage—driving the entire analog industry.
Single agonists: exenatide to semaglutide
Exendin-4 (from Gila monster venom biology) inspired exenatide. Later human-GLP-1–based analogs used residue changes and fatty-acid side chains (e.g., semaglutide) for weekly pharmacokinetics in approved products.
Dual agonists: tirzepatide
Tirzepatide engages GIP and GLP-1 receptors. Dual agonism is a design bet that multi-receptor pharmacology can outperform single-pathway drugs for metabolic endpoints.
Triple agonists: retatrutide
Retatrutide adds glucagon receptor activity to the incretin story, aiming to influence energy expenditure as well as intake and glycemia. It is a major clinical-research topic and a high-volume educational query.
Amylin joins the cast
Cagrilintide and amylin biology appear in combination strategies with incretins. Metabolic peptide science is now a multi-hormone network problem, not a single-target story.
Approved drugs vs research powders
Pharmacy products are manufactured and labeled under drug law. Research-grade powders using the same INN names are a different legal and quality universe. Educational sites should never blur that line.
FAQ
Is semaglutide a research peptide?+
Semaglutide is an approved active ingredient in prescription medicines in many countries. Unregulated powders sold as “research semaglutide” are not the same as licensed products.
Tirzepatide vs semaglutide?+
Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 agonist. Mechanisms and clinical programs differ—compare primary literature and labels, not anecdotes.